Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of three drugs: - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and RNA transcription by cross-linking DNA strands, leading to cell death. - **Fluorouracil (5-FU)** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and function. - **Leucovorin (folinic acid)** enhances the cytotoxic effects of 5-fluorouracil by stabilizing the binding of 5-FU's active metabolite to thymidylate synthase. This combination has been studied in various cancers including advanced pancreatic cancer and metastatic breast cancer. Leucovorin acts as a biochemical modulator to increase the efficacy of 5-fluorouracil. Cyclophosphamide may further enhance this effect[1][2]. The regimen aims to maximize antitumor activity while managing toxicity.
- Other names
- cyclophosphamide + 5-fluorouracil + leucovorinC+F+LC+5-FU+LV
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cyclophosphamide + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + fluorouracil + leucovorin.